A
Andreas H. Diacon
Researcher at University of Cape Town
Publications - 233
Citations - 11423
Andreas H. Diacon is an academic researcher from University of Cape Town. The author has contributed to research in topics: Tuberculosis & Mycobacterium tuberculosis. The author has an hindex of 48, co-authored 210 publications receiving 9253 citations. Previous affiliations of Andreas H. Diacon include DST Systems & Dartmouth–Hitchcock Medical Center.
Papers
More filters
Journal ArticleDOI
The diarylquinoline TMC207 for multidrug-resistant tuberculosis
Andreas H. Diacon,Alexander S. Pym,Martin P. Grobusch,R. F. Patientia,Roxana Rustomjee,Liesl Page-Shipp,Christoffel Pistorius,Rene Krause,Mampedi Bogoshi,Gavin J. Churchyard,Amour Venter,Jenny Allen,Juan Carlos Palomino,Tine De Marez,Rolf van Heeswijk,Nacer Lounis,Paul Meyvisch,Johan Verbeeck,Wim Parys,Karel de Beule,Koen Andries,David F Mc Neeley +21 more
TL;DR: The clinical activity of TMC207 validates ATP synthase as a viable target for the treatment of tuberculosis.
Journal ArticleDOI
Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline
Andreas H. Diacon,Alexander S. Pym,Martin P. Grobusch,Jorge M. de los Rios,Eduardo Gotuzzo,Irina Vasilyeva,Vaira Leimane,Koen Andries,Nyasha Bakare,Tine De Marez,Myriam Haxaire-Theeuwes,Nacer Lounis,Paul Meyvisch,Els De Paepe,Rolf van Heeswijk,Brian Dannemann +15 more
TL;DR: The addition of bedaquiline to a preferred background regimen for 24 weeks resulted in faster culture conversion and significantly more culture conversions at 120 weeks, as compared with placebo.
Journal ArticleDOI
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis
Francesca Conradie,Andreas H. Diacon,Nosipho Ngubane,Pauline Howell,Daniel Everitt,Angela M. Crook,Mendel Carl M,Erica Egizi,Joanna Moreira,Juliano Timm,Timothy D. McHugh,G Wills,Anna Bateson,Robert D Hunt,Christo van Niekerk,Mengchun Li,Morounfolu Olugbosi,Melvin Spigelman +17 more
TL;DR: The combination of bedaquiline, pretomanid, and linezolid led to a favorable outcome at 6 months after the end of therapy in a high percentage of patients with highly drug-resistant forms of tuberculosis; some associated toxic effects were observed.
Journal ArticleDOI
14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial
Andreas H. Diacon,Rodney Dawson,Florian von Groote-Bidlingmaier,Gregory Symons,Amour Venter,Peter R. Donald,Christo van Niekerk,Daniel Everitt,Helen Winter,Piet J. Becker,Mendel Carl M,Melvin Spigelman +11 more
TL;DR: PA-824-moxifloxacin-pyrazinamide is potentially suitable for treating drug-sensitive and multidrug-resistant tuberculosis and can contribute to reducing the time needed to develop new antituberculosis regimens.
Journal ArticleDOI
Diagnostic tools in tuberculous pleurisy: a direct comparative study
Andreas H. Diacon,B. W. Van de Wal,C Wyser,JP Smedema,Juanita Bezuidenhout,Chris T. Bolliger,Gerhard Walzl +6 more
TL;DR: A combination of pleural fluid adenosine deaminase, differential cell count and closed needle biopsy has a high diagnostic accuracy in undiagnosed exudative pleural effusions in areas with high incidences of tuberculosis and might substitute medical thoracoscopy at considerably lower expense in resourcepoor countries.